Role of Toll like receptor 4 signaling pathway in the secondary damage induced by experimental spinal cord injury

Immunobiology

Volumn 220, Issue 9, 2015, Pages 1039-1049

  Impellizzeri, Daniela ^a   Ahmad, Akbar ^a   Di Paola, Rosanna ^a   Campolo, Michela ^a   Navarra, Michele ^a   Esposito, Emanuela ^a   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Apoptosis; MyD88; Nuclear factor B; Spinal cord injury; Toll like receptor 4

Indexed keywords

3 NITROTYROSINE; BETA INTERFERON; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; GLIAL FIBRILLARY ASTROCYTIC PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; IRF3 PROTEIN, MOUSE; MYD88 PROTEIN, MOUSE; NERVE PROTEIN; NOS2 PROTEIN, MOUSE; RELA PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTAL SPINAL CORD INJURY; HINDLIMB; INJURY SEVERITY; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE MODEL; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; C3H MOUSE; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; KNOCKOUT MOUSE; PATHOLOGY; SECRETION (PROCESS); SPINAL CORD INJURY;

ANIMALS; ANTIGENS, CD11B; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; GENE EXPRESSION REGULATION; HINDLIMB; INFLAMMATION; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; INTERLEUKIN-1BETA; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; NERVE TISSUE PROTEINS; NEUROIMMUNOMODULATION; NEUTROPHIL INFILTRATION; NITRIC OXIDE SYNTHASE TYPE II; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION; SPINAL CORD INJURIES; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84983120917     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.05.013     Document Type: Article

References (43)

1. Ahmad A., Crupi R., Campolo M., Genovese T., Esposito E., Cuzzocrea S. Absence of TLR4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice. PLOS ONE 2013, 8:e57208. 10.1371/journal.pone.0057208.
2. Akira S. TLR signaling. Curr. Top. Microbiol. Immunol. 2006, 311:1.
3. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499.
4. Anderson K.V., Bokla L., Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 1985, 42:791.
5. Bar-Peled O., Knudson M., Korsmeyer S.J., Rothstein J.D. Motor neuron degeneration is attenuated in bax-deficient neurons in vitro. J. Neurosci. Res. 1999, 55:542.
6. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J. Neurotrauma 2006, 23:635. 10.1089/neu.2006.23.635.
7. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2:907.
8. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J., et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N. Engl. J. Med. 1990, 322:1405.
9. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J.C., Marshall L.F., et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second national acute spinal cord injury study. J. Neurosurg. 1992, 76:23.
10. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Administration of methylprednisolone for 24 or 48hours or tirilazad mesylate for 48hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial. National acute spinal cord injury study. J. Am. Med. Assoc. 1997, 277:1597.
11. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M.G., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K., Wagner F., Wilberger J.E., Winn H.R., Young W. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third national acute spinal cord injury randomized controlled trial. J. Neurosurg. 1998, 89:699.
12. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248.
13. Buchanan M.M., Hutchinson M., Watkins L.R., Yin H. Toll-like receptor 4 in CNS pathologies. J. Neurochem. 2010, 114:13. 10.1111/j.1471-4159.2010.06736.x.
14. Cuzzocrea S., Riley D.P., Caputi A.P., Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. 2001, 53:135.
15. Eng L.F., Ghirnikar R.S. GFAP and astrogliosis. Brain Pathol. 1994, 4:229.
16. Felts P.A., Woolston A.M., Fernando H.B., Asquith S., Gregson N.A., Mizzi O.J., Smith K.J. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain 2005, 128:1649.
17. Galluzzi L., Vacchelli E., Eggermont A., Fridman W.H., Galon J., Sautes-Fridman C., Tartour E., Zitvogel L., Kroemer G. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012, 1:699. 10.4161/onci.20696.
18. Genovese T., Esposito E., Mazzon E., Crisafulli C., Paterniti I., Di Paola R., Galuppo M., Bramanti P., Cuzzocrea S. PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol. Res. 2009, 59:338. 10.1016/j.phrs.2009.01.018.
19. Griffiths M., Neal J.W., Gasque P. Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int. Rev. Neurobiol. 2007, 82:29. 10.1016/S0074-7742(07)82002-2.
20. Impellizzeri D., Esposito E., Mazzon E., Paterniti I., Di Paola R., Bramanti P., Morittu V.M., Procopio A., Perri E., Britti D., Cuzzocrea S. The effects of a polyphenol present in olive oil, oleuropein aglycone, in an experimental model of spinal cord injury in mice. Biochem. Pharmacol. 2012, 83:1413. 10.1016/j.bcp.2012.02.001.
21. Kaczorowski D.J., Mollen K.P., Edmonds R., Billiar T.R. Early events in the recognition of danger signals after tissue injury. J. Leukoc. Biol. 2008, 83:546.
22. Lehnardt S., Lachance C., Patrizi S., Lefebvre S., Follett P.L., Jensen F.E., Rosenberg P.A., Volpe J.J., Vartanian T. The Toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 2002, 22:2478.
23. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8514.
24. Martins K.A., Steffens J.T., van Tongeren S.A., Wells J.B., Bergeron A.A., Dickson S.P., Dye J.M., Salazar A.M., Bavari S. Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLOS One 2014, 9:e89735. 10.1371/journal.pone.0089735.
25. Maslinska D., Laure-Kamionowska M., Maslinski S. Toll-like receptors in rat brains injured by hypoxic-ischaemia or exposed to staphylococcal alpha-toxin. Folia Neuropathol. 2004, 42:125.
26. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 2007, 19:3.
27. Mullane K.M., Kraemer R., Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods 1985, 14:157.
28. Nockels R., Young W. Pharmacologic strategies in the treatment of experimental spinal cord injury. J. Neurotrauma. 1992, 9(Suppl. 1):S211.
29. Popovich P.G. Immunological regulation of neuronal degeneration and regeneration in the injured spinal cord. Prog. Brain Res. 2000, 128:43.
30. Qin H., Wilson C.A., Lee S.J., Benveniste E.N. IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB J. 2006, 20:985. 10.1096/fj.05-5493fje.
31. Samadikuchaksaraei A. An overview of tissue engineering approaches for management of spinal cord injuries. J. Neuroeng. Rehabil. 2007, 4:15.
32. Szabo C., Dawson V.L. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci. 1998, 19:287.
33. Tanga F.Y., Nutile-McMenemy N., DeLeo J.A. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5856. 10.1073/pnas.0501634102.
34. Tani M., Glabinski A.R., Tuohy V.K., Stoler M.H., Estes M.L., Ransohoff R.M. In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am. J. Pathol. 1996, 148:889.
35. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., Miyake K., Freudenberg M., Galanos C., Simon J.C. Oligosaccharides of Hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med. 2002, 195:99.
36. Toshchakov V., Jones B.W., Perera P.Y., Thomas K., Cody M.J., Zhang S., Williams B.R., Major J., Hamilton T.A., Fenton M.J., Vogel S.N. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 2002, 3:392.
37. Trivedi A., Olivas A.D., Noble-Haeusslein L.J. Inflammation and spinal cord injury: infiltrating leukocytes as determinants of injury and repair processes. Clin. Neurosci. Res. 2006, 6:283.
38. Verma I.M. Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann. Rheum. Dis. 2004, 63(Suppl. 2):ii57.
39. Wilhelmsson U., Bushong E.A., Price D.L., Smarr B.L., Phung V., Terada M., Ellisman M.H., Pekny M. Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17513.
40. Wu C.C., Crain B., Yao S., Sabet M., Lao F.S., Tawatao R.I., Chan M., Smee D.F., Julander J.G., Cottam H.B., Guiney D.G., Corr M., Carson D.A., Hayashi T. Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand. J. Innate Immun. 2014, 6:315. 10.1159/000355217.
41. Xu L., Zhan Y., Wang Y., Feuerstein G.Z., Wang X. Recombinant adenoviral expression of dominant negative IkappaBalpha protects brain from cerebral ischemic injury. Biochem. Biophys. Res. Commun. 2002, 299:14.
42. Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K., Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 2002, 169:6668.
43. Zekki H., Feinstein D.L., Rivest S. The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol. 2002, 12:308.